Chemotherapy for androgen-independent prostate cancer

被引:20
作者
Petrylak, DP [1 ]
机构
[1] Columbia Univ, Med Ctr, New York, NY 10032 USA
关键词
chemotherapy; androgen-independent prostate cancer;
D O I
10.1007/s00345-004-0482-0
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The evolution of taxanes as treatment for androgen-independent prostate cancer hes emerged from both the laboratory and clinic. Docetaxel is a potent in vitro inhibitor of Bcl-2, an antiapoptotic gene. Phase I and II studies with docetaxel alone or in combination with estramustine demonstrated promissing median survivals of 14-23 months, higher than what would have been expected for historic controls. Two randomized trials have proven the superiority of docetaxel based treatment in improving survival in men with androgen-independent prostate cancer. SWOG 99-16 and TAX 327 found that docetaxel-based therapy reduced the risk of death by 20-24% when compared to mitoxantrone-based therapy. Future trials will build on docetaxel-based combinations with novel targeted agents.
引用
收藏
页码:10 / 13
页数:4
相关论文
共 32 条
[1]   Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer [J].
Beer, TM ;
Pierce, WC ;
Lowe, BA ;
Henner, WD .
ANNALS OF ONCOLOGY, 2001, 12 (09) :1273-1279
[2]   Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate [J].
Berry, W ;
Dakhil, S ;
Gregurich, MA ;
Asmar, L .
SEMINARS IN ONCOLOGY, 2001, 28 (04) :8-15
[3]  
Berry William R, 2004, Clin Prostate Cancer, V3, P104, DOI 10.3816/CGC.2004.n.020
[4]   BCL-2 in prostate cancer: A minireview [J].
Catz, SD ;
Johnson, JL .
APOPTOSIS, 2003, 8 (01) :29-37
[5]  
DAHLLOF B, 1993, CANCER RES, V53, P4573
[6]   Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer [J].
Dahut, WL ;
Gulley, JL ;
Arlen, PM ;
Liu, Y ;
Fedenko, KM ;
Steinberg, SM ;
Wright, JJ ;
Parnes, H ;
Chen, CC ;
Jones, E ;
Parker, CE ;
Linehan, WM ;
Figg, WD .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2532-2539
[7]  
DREICER R, 2004, P AM SOC CLIN ONC 20, V22, P4664
[8]  
Haldar S, 1996, CANCER RES, V56, P1253
[9]   Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase network phase III trial [J].
Hudes, G ;
Einhorn, L ;
Ross, E ;
Balsham, A ;
Loehrer, P ;
Ramsey, H ;
Sprandio, J ;
Entmacher, M ;
Dugan, W ;
Ansari, R ;
Monaco, F ;
Hanna, M ;
Roth, B .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3160-3166
[10]   Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study [J].
Kantoff, PW ;
Halabi, S ;
Conaway, M ;
Picus, J ;
Kirshner, J ;
Hars, V ;
Trump, D ;
Winer, EP ;
Vogelzang, NJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2506-2513